Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities
I'm PortAI, I can summarize articles.
Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating for Fate Therapeutics with a $2.00 price target. The stock closed at $0.96. Ahmad, a 3-star analyst, has a 1.8% average return and a 54.71% success rate. Fate Therapeutics also received a Hold from Needham's Gil Blum, while H.C. Wainwright upgraded it to Buy on October 31.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments